Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5200_Библиотеки_им_академика_М_И_Перельмана
.pdf
abuse.
AdverseEvents
Adverse effects includelipid elevations, abnormal liver function,alopecia, skin peeling, pruritus,dry
skin,drymouth,epistaxis,paresthesia,paronychia,andpseudotumorcerebri.
Interactions
Drug interactions occur with methotrexate (MTX, Rheumatrex), alcohol, and progestin-only
contraceptives.Womenmustnotingestalcoholduringtherapyorfor2monthsafterwardbecausealcohol
prolongstheteratogenicpotentialofthedrug.
Methotrexate
MTXisusedtotreatgeneralizedpsoriasis.
MechanismofAction
MTXinhibitsfolicacidreductase,resultingintheinhibitionofcellularreplicationandselectionofthe
mostrapidlydividingcells.
Dosage
Theinitialdoseis7.5mgaweekadministeredinthreedosesovera24-hourperiod.Itisthentitratedtoa
doseof12.5to25mgaweek.Withimprovementinthedisease,thedoseisreducedandotheragentsare
used.Folicacid,1mgdaily,shouldbetakenonnontreatmentdays.
Contraindications
MTXis contraindicatedinpregnancy andlactation,andthe drugis usedwithcautioninpatients with
renal,hepaticdisordersandleukopenia.
AdverseEvents
Commonadverseeffectsincludeheadache,blurredvision,fatigue,malaise,gastrointestinal(GI)distress,
gingivitis,hepatictoxicity,bonemarrowdepression,rashes,alopecia,andchillsandfever.
Interactions
There is an increased risk of toxicity if the patient is taking other medications, such as salicylates,
phenytoin(Dilantin),andsulfonamides.UseofMTXalsodecreasestheserumlevelofdigoxin(Lanoxin).
Cyclosporine

MechanismofAction
Cyclosporinesuppressescell-mediatedimmunereactionsandhumoralimmunity.Itinhibitstheproduction
ofIL-2,whichisresponsibleforproducingTcellproliferation.Cyclosporinepromotesrapidremission
in severe psoriasis flares. It is usually used for short-term treatment (3–6 months) for severe
exacerbationsduetotoxicity.
Dosage
Themaximumdoseforuseinpsoriasis is 2to5 mg/kg/d.Maintenancetherapyis atlower doses. Itis
suppliedin100-mgtabletsanddosedtwicedaily.
Contraindications
Cyclosporineiscontraindicatedinpregnancyandlactationandmustbeusedwithcautioninpatientswith
impairedrenalfunctionandmalabsorption.
AdverseEvents
Adverse effects include hypertension and nephrotoxicity, as well as tremor, gingival hyperplasia, GI
upset,hirsutism,andacne.Lesionscanrecurwithindaystoweeksaftertreatmentends,andreboundswith
worsesymptomsarenotuncommon.
Interactions
Cyclosporineuseincreasestheriskfornephrotoxicityifthepatientusesothernephrotoxicagents,andit
also increases the risk for digoxin toxicity. Cyclosporine interacts with lovastatin, diltiazem, and
ketoconazole,anditstherapeuticeffectisdecreasedwithconcomitanthydantoin(Dilantin),rifampin,and
sulfonamideuse.Patientsmustavoidgrapefruitproducts.
PHOSPHODIESTERASE4INHIBITORS
Apremilast(Otezla)
MechanismofAction
Apremilast, an oral agent, is a small molecule specific to cyclic adenosine monophosphate. The
underlyingmechanismisnotwellunderstood.Nopriorlabstudiesarerequiredpriortoinitiatingtherapy,
unliketherequirementwithmostotheragents.
Dosage
Astarterpackisdesignedtoallowfortitrationtomaintenancedose30mgtwicedaily.

Contraindications
Patientswithaknownhypersensitivitytoapremilastanditsingredients.
AdverseEvents
ThemostcommonadverseeventisGIdistressanddiarrheawhichforsomemaybeself-limiting.Weight
lossmayalsooccurasasideeffect.Cautionisneededwithuseinpatientswithahistoryofdepression,
asthisdrugmayexacerbatesymptoms.
Interactions
Apremilast activity is decreased when coadministered with strong cytochrome P-450 inducers (i.e.,
rifampin),andmaydecreaseefficacy.
BIOLOGICS
ThebiologicsinteractwithspecifictargetsintheTcell–mediatedinflammatoryprocess. Theyhavean
antiinflammatory effect through the inhibition of cytokine release, prevention of T cell activation,
depletionofpathologicTcells,andblockingoftheinteractionsthatleadtoTcellactivationormigration
intothetissue.TheyalsoalterthebalanceoftheTcelltypesandinhibitkeyinflammatorycytokines,such
as TNF-alpha inhibitors (Enbrel and Humira), IL-17 blockage (Taltz Cosentyx and Siliq), IL-12/23
blockade(Stelara),andIL-23antagonists(Tremfya,Ilumya,Skyrizi).Testingfortuberculosis(TB)prior
to drug initiation is recommended by placing purified protein derivative (PPD) intradermal or
Quantiferon Gold via blood samples for all agents. For individuals who have received the Bacillus
Calmette-Guerin (BCG) vaccine, a chest X-ray is recommended. If tested positive, a consult to the
infectious diseasedepartmentis recommendedfortreatmentpriorto biologic use.Due tothe immunesuppressivenatureofthesedrugs,otherlaboratorystudiesrecommendedincludeCBC,CMP,lipidpanel,
hepatitisB(musttreatpriortobiologicuse),andhepatitisC.
TNF-alphainhibitorswerethefirstbiologicsusedtotreatmoderatetosevereplaquepsoriasis. The
followingarecurrentlyapproveddrugsinthisclass:
Etanercept(Enbrel)
Infliximab(Remicade)
Adalimumab(Humira)
Certolizumabpegol(Cimzia)
MechanismofAction
BindsandinhibitsTNF,thecytokinethathelpsregulatethebody’simmuneresponsetoinflammation.Itis
usedtotreatmoderatetoseverepsoriasis.
Dosage
Etanercept(Enbrel)inpsoriasis isdosedat50mgsubcutaneouslytwice aweekinitiallyfor3months.

Themaintenancedose is 50 mgsubcutaneouslyweekly, withamaximum of25mggivenatonesite.It
requirestwoinjectionsinseparatesites.Infliximab(Remicade)isgivenbyintravenousinfusionoverat
least 2 hours. The dose is 5 mg/kg at week 0, week 2, and week 6 and then once every 8 weeks.
Adalimumab (Humira) is administered subcutaneously initially80 mgfollowed by 40 mgevery other
weekstartingtheweekaftertheinitialdose.Certolizumab (Cimzia)isdosedat400mgsubcutaneously
initiallyandtheneveryotherweek.
Contraindications
Contraindications include live vaccines, malignancy, and/or active infection. Caution is exercised in
femalesofreproductiveage.Itisnotrecommendedforpatientsinpregnancyorthosewithimpairedrenal
function,asthma,historyofblooddyscrasias,demyelinatingdisease,thatis,multiplesclerosis,historyof
chronicrecurrentinfections,and/ormalignancy.Infliximabiscontraindicatedinpatientswithmoderateto
severecongestiveheartfailure.
AdverseEvents
Adverse events include infection, injection site reaction, localized erythema, rash, upper respiratory
infections,abdominalpain,andvomiting.
Interactions
There is an increased chance of infection with those individuals who are immunocompromised. Live
vaccinesshouldbegivenpriortoinitiationoftherapyordosageshouldbewithheldfor2weeksbefore
and then 1 month after administration of the vaccine to ensure adequate immune response. Similar
discontinuationusedforvoluntarysurgicalprocedures.
Ustekinumab
MechanismofAction
Ustekinumab(Stelara)isahumanIL-12andIL-23antagonist.
Dosage
Administeredsubcutaneously,itisavailableintwoweight-baseddoses:Patientsweighinglessthan100
kg(220lbs)receivea45-mgdoseandthoseweighinggreaterthan100kg(220lbs)receive90mgfour
timesayear.
Contraindications
Ustekinumabisnotrecommendedforpatientswithsensitivitytoanyoftheexcipients.
AdverseEvents

Mayincludenasopharyngitisandupperrespiratorytractinfections.Seriousinfectionsandmalignancies
mayoccur.
Interactions
Livevaccinesshouldnotbegiventopatientstakinguste-kinumab.
Interleukin-17Inhibitors
MechanismofAction
Secukinumab (Cosentyx), Ixekizumab (Taltz), and Brodalumab (Siliq) are monoclonal antibodies that
bindtoIL-17,blockingtheabilityofthecytokinetointeractwithitsreceptor.
Dosing
Thefollowingarethedosages:
Secukinumab—300mgadministered subcutaneously(in divided doses of150 each) every weekfor 5
weeksandthenonceeverymonth
Ixekizumab—80mgadministeredevery2weeksfor3monthsandthenonceevery4weeks
Brodalumab—210mgadministeredatweeks0,1,and2andthenonceevery2weeks.
Contraindications
Similartoallotherbiologicagents.
AdverseEvents
Adverseeventsaresimilartothoseofallotherbiologicagents.
Contraindications
Nolivevaccines.
Interleukin-23inhibitors
MechanismofAction
Guzelkumab(Tremfya),Tildrakizumab(Ilumya),andrisankizumab(Skyrizi)blockIL-23.InhibitionofIL23cytokinepreventsthecascadeofinflammatorycells.ByblockingtheIL23pathway,itactivatesand
maintainstheThelper17pathway.
Dosing

Guselkumab 100 mg subcutaneously at weeks 0, 4, and then every 8 weeks. Tildrakizumab 100 mg
subcutaneouslyatweeks0,4,andthenevery12weeks.
Contraindications
Similartoallotherbiologicagents.
AdverseEvents
Similartoallotherbiologicagents.
Contraindications
Nolivevaccines.
Biosimilarsarealsonowavailableforsomeoftheseagents.
SelectingtheMostAppropriateAgent
Selectionoftherapydependsonthepatient’sage,typeoflesion,involvement,andprevioustreatments.
Mildtorelativelymoderatepsoriasis (lessthan10%BSA)canbetreatedbya primarycareprovider.
Topicaltreatmentofpsoriasisisthefirststepandisusuallyeffectiveformilddisease.Patientswithmore
generalizeddiseasearereferredtoadermatologistfortreatmentandphototherapy,andsystemicagents
areused(Table14.2andFigure14.1).
Itappearsthatcombinationtherapywithsystemicagentsandothermodalitieshavesynergisticvalue.In
combination therapy,the dose canoftenbe reduced, causingless toxicity fromhigher dose individual
drugs. Systemic therapy with phototherapy is also effective, but time constraints of biweekly therapy
hinderuse.
First-LineTherapy
First-linetherapyincludesmoisturizersandtopicalsteroids.For2weeks,ahigh-potencyorveryhigh–
potencytopicalsteroidisappliedtwicedailyandcoveredbyanocclusivedressingofplasticwrap.A
low-potency preparation is used on the face and intertriginous areas. An ointment is recommended
becauseitprovidesthemostmoisture.Anemollientisalsousedtokeeptheskinhydrated.
Second-LineTherapy
Ifthepatient’sresponsetofirst-linetherapyisnotoptimal,severalsecond-linechoicesareavailable.If
thepatientshowsagoodresponse,therapymayconsistofaweek’srestfromthetopicalcorticosteroids.
Another option is the use of corticosteroids twice daily weekends and vitamin D analog twice daily
weekdays.Limitingtheuseofhigh-potencytopicalcorticosteroidstoonceortwiceaweekandaddinga
lower-strengthoravitaminDanalogtwicedailytotheregimenareotheroptions.Thisproducesabetter
resultthaneitherdrugusedalone.Thetopicalcorticosteroidhelpscleartheplaquesandreducesirritation
fromthevitaminDpreparation.

Third-LineTherapy
Iffirst-andsecond-linetreatmentsfail,apatientisreferredtoadermatologist,whomayuseultraviolet
(UV)Blighttreatments,antimetabolites,biologicagents,orpsoralensplusUVA=PUVA.
TABLE14.2
RecommendedOrderofTreatmentforPsoriasis
Order Therapy Comments
First
line
High-potencytopicalcorticosteroidsappliedtomoistskinanduse
ofocclusivedressingtwicedailyfor2weeks.Useemollientsas
adjuncttherapy
Usewhen<10%ofbodysurfacearea
isaffected
Second
line
Ifthepatientrespondedwelltofirst-linetherapy,providea1-week
restfromthetopicalcorticosteroidsandinitiateanother2weeksof
therapywiththesameagentfortwomoretimes
Ifthereisremission,applyingthe
topicalsteroidsonceortwiceaweek
maymaintainremission
OR
Taperthehigh-potencytopicalcorticosteroidusetoonceortwicea
weekandaddavitaminDanalogtwicedaily
Third
line
Refertodermatologistforsystemictherapy Forusewith>20%bodysurfacearea,
UVBisusedwithcoaltaroranthralin;
PUVAisusedwithpsoralens
PUVA,PsoralenandultravioletAtherapy;UVB,ultravioletBtreatments.

FIGURE14–1Treatmentalgorithmforpsoriasis.BSA,bodysurfacearea.
MONITORINGPATIENTRESPONSE
The goal of chronic topical corticosteroid therapy is to use the lowest effective potency to control
symptoms.Initially,follow-upmayhavetobedonemonthlyandthenmayprogresstoevery2to3months.
PATIENTEDUCATION

DrugInformation
In patients with psoriasis, education regarding stress reduction and symptom control is important to
preventprogressionofdiseaseandreachtherapygoals.Thepopulationshouldunderstandthatpsoriasis
isnotcontagious.Inaddition,referralforcounselingmayhelpwithrelatedemotionalissues.
Psychosocial concerns should be addressed since this condition can affect self-esteem and social
interactionswithothers.Patientsmayalsobenefitfrominformationandsupportfromgroupssuchasthe
NationalPsoriasisFoundation(1-800-723-9166,www.psoriasis.org).
Demonstration for proper application of topical steroids is an important aspect of care. The
medicationsaretobeusedtwicedailyandappliedlightlyonmoistskinformaximumbenefit.
LifestyleChanges
Symptomcontrol,ratherthancure,isthegoaloftherapy.Patientsmayhelpcontrolsymptomsbyexposing
their skin to the sun. This should be accomplished by gradually increasing the length of exposure.
Emphasisshouldbeplacedontheimportanceofusingsunscreenandavoidingsunburn.
Topreventinfection,patientsmusttakecaretonotcutthelesionswhenshaving(iftherearelesionsin
thearea).Psoriasiscanbetriggeredbyinfections,stress,andchangesinclimatethatcandryskin.These
shouldbeavoidedwhenpossible.
ComplementaryandAlternativeMedicine
Fishoilisthoughttoaltertheimmuneresponseandinsmallquantitiescanrelieveitchingandscaling.It
hasaneffectonchronicplaquepsoriasisindosesof6to15gdaily.Analternativeistoeatfishthricea
week.Aloeverawas showntobeeffectiveintreatmentofpsoriasis.Ina16-weekstudy,therewasan
82.8%clearingofpsoriaticplaquebyuseof0.5%hydrophilicaloeveracreamthricedaily.Glucosamine
has been shown to relieve some of the pain of arthritis from psoriasis. Dietary changes to avoid
inflammatorysubstancesareencouraged.
CASESTUDY1
P.B.isa58-year-oldwomanwithahistoryofhypertension.Sheseekstreatmentforscatteredplaques
with a silvery-white scale on her elbows, forearms, and knees. The body surface area affected is
approximately8%.Sheis veryself-consciousaboutthelesions:“Ijustwantthemtogoaway.” Her
medicationsincludepropranolol40 mgthricedailyandfurosemide40mgdaily.Shehasapositive
familyhistoryofpsoriasisandreportshighlevelsofstressinherjobandlife.Shesmokesapackof
cigarettesperday.
Diagnosis:Psoriasis
1.ListspecificgoalsfortreatmentforP.B.
Answer: Will state relief from itch. Understands the possible side effects from topical steroid
therapy.

2.Whatdrugtherapywouldyouprescribe?Why?
Answer:Classonetopicalsteroid.Provideimprovementinscale,itch,andinflammation.
3.Whataretheparametersformonitoringthesuccessofthetherapy?
Answer:Thinningofscale,relieffromitch.
4.Discussspecificpatienteducationbasedontheprescribedtherapy.
Answer:Limituseofpotenttopicalsteroids.Theconditionwaxesandwanes.
5.Listoneortwoadversereactionsfortheselectedagentthatwouldcauseyoutochangetherapy.
Answer:Striae,skinthinning,hypopigmentation.
6.Whatwouldbethechoiceforsecond-linetherapy?
Answer:VitaminDanalog.
7.Whatover-the-counteroralternativemedicationswouldbeappropriateforP.B.?
Answer:Moisturizers.
8.WhatlifestylechangeswouldyourecommendtoP.B.?
Answer:Smokingcessation.Stressreductiontechniques.
9.Describeoneortwodrug–drugordrug–foodinteractionsfortheselectedagent.
Answer:Topicalagentsshouldbeusedatalternatingintervalsratherthandilutingtheeffect.
CASESTUDY2
J.D.is a 46-year-old male withnew onsetplaquepsoriasis.Familyhistoryis positive onmaternal
side.Thelesionsareitchy,bleeding,andrubbingonclothing.Heisseekingaquickfixandwantstobe
rid ofthisrash.Hehasnotbeeninforhisannualappointmentforthelastfewyears,sonobaseline
laboratoryresultsexist.He denies jointpain,butlesionsareevidentonextensor surfacesincluding
elbowsandkneesandondifficult-to-treatareassuchasscalp.Nootherhealthconcernsandcurrently
takingnodailymedications.Headmitstoafamilyhistoryofirritablebowelsyndrome.
Diagnosis:Psoriasis
Соседние файлы в папке Библиотека им академика М.И. Перельмана
